Lung Cancer
Volume 68, Issue 1 , Pages 1-9 , April 2010

Are adenosquamous lung carcinomas a simple mix of adenocarcinomas and squamous cell carcinomas, or more complex at the molecular level?

  • Kristell Bastide

      Affiliations

    • CEA, DSV, IRCM, SREIT, Laboratoire de Cancérologie Expérimentale, BP6, Fontenay-aux-Roses Cedex F-92265, France
    • Corresponding Author InformationCorresponding author. Tel.: +33 1 46 54 94 26; fax: +33 1 46 54 88 86.
    • ,
  • Nicolas Ugolin

      Affiliations

    • CEA, DSV, IRCM, SREIT, Laboratoire de Cancérologie Expérimentale, BP6, Fontenay-aux-Roses Cedex F-92265, France
    • ,
  • Céline Levalois

      Affiliations

    • CEA, DSV, IRCM, SREIT, Laboratoire de Cancérologie Expérimentale, BP6, Fontenay-aux-Roses Cedex F-92265, France
    • ,
  • Jean-François Bernaudin

      Affiliations

    • Service d’Histologie-Biologie Tumorale, Equipe de Recherche ER 2 UPMC, Université Paris 6, Hôpital Tenon, Paris F-75020, France
    • ,
  • Sylvie Chevillard

      Affiliations

    • CEA, DSV, IRCM, SREIT, Laboratoire de Cancérologie Expérimentale, BP6, Fontenay-aux-Roses Cedex F-92265, France

Received 12 May 2009 ,Revised 17 September 2009 ,Accepted 2 November 2009.

References 

  1. Alberg AJ, Brock MV, Samet JM. Epidemiology of lung cancer: looking to the future. J Clin Oncol. 2005;23(14):3175–3185
  2. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin. 2005;55(2):74–108
  3. Stancu M, Libbey PN. In:  Weitberg AB editors. Cancer of the lung: from molecular biology to treatment guidelines. Totowa, NJ: Humana; 2002;p. 35–80
  4. Travis WD, Colby TV, Corrin B, Shimosato Y, Brambilla E. Histological typing of lung and pleural tumors. Berlin: Springer-Verlag; 1999;
  5. Hsia JY, Chen CY, Hsu CP, Shai SE, Wang PY. Adenosquamous carcinoma of the lung Surgical results compared with squamous cell and adenocarcinoma. Scand Cardiovasc J. 1999;33(1):29–32
  6. Gawrychowski J, Brulinski K, Malinowski E, Papla B. Prognosis and survival after radical resection of primary adenosquamous lung carcinoma. Eur J Cardiothorac Surg. 2005;27(4):686–692
  7. Nakagawa K, Yasumitu T, Fukuhara K, Shiono H, Kikui M. Poor prognosis after lung resection for patients with adenosquamous carcinoma of the lung. Ann Thorac Surg. 2003;75(6):1740–1744
  8. Kanazawa H, Ebina M, Ino-Oka N, Shimizukawa M, Takahashi T, Fujimura S, et al. Transition from squamous cell carcinoma to adenocarcinoma in adenosquamous carcinoma of the lung. Am J Pathol. 2000;156(4):1289–1298
  9. Monchaux G, Morlier JP, Altmeyer S, Debroche M, Morin M. Influence of exposure rate on lung cancer induction in rats exposed to radon progeny. Radiat Res. 1999;152(6 Suppl.):S137–S140
  10. Hahn FF, Boorman GA. Neoplasia and preneoplasia of the lung. In:  Bannasch P,  Gössner W editor. Pathology of neoplasia and preneoplasia in rodents, EULEP Color Atlas. vol. 2:Stuttgart/New York: Schattauer; 1997;pp. 29–42
  11. Chevillard S, Ugolin N, Vielh P, Ory K, Levalois C, Elliott D, et al. Gene expression profiling of differentiated thyroid neoplasms: diagnostic and clinical implications. Clin Cancer Res. 2004;10(19):6586–6597
  12. Klising-Sireul E, Rigaud O, Ory K, Ugolin N, Lebeau J, Levalois C, et al. Transcriptional response of wild-type and ataxia telangiectasia lymphoblasts following exposure to equitoxic doses of ionizing radiation. J Radiat Res (Tokyo). 2006;47(3–4):259–272
  13. Bishay K, Ory K, Olivier MF, Lebeau J, Levalois C, Chevillard S. DNA damage-related RNA expression to assess individual sensitivity to ionizing radiation. Carcinogenesis. 2001;22(8):1179–1183
  14. Chevillard S, Muller A, Levalois C, Laine-Bidron C, Vielh P, Magdelenat H. Reverse transcription-polymerase chain reaction (RT-PCR) assays of estrogen and progesterone receptors in breast cancer. Breast Cancer Res Treat. 1996;41(1):81–89
  15. Oudard S, Levalois C, Andrieu JM, Bougaran J, Validire P, Thiounn N, et al. Expression of genes involved in chemoresistance, proliferation and apoptosis in clinical samples of renal cell carcinoma and correlation with clinical outcome. Anticancer Res. 2002;22(1A):121–128
  16. Vandesompele J, De Preter K, Pattyn F, Poppe B, Van Roy N, De Paepe A, et al. Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol. 2002;3(7):RESEARCH0034
  17. Dano L, Guilly MN, Muleris M, Morlier JP, Altmeyer S, Vielh P, et al. CGH analysis of radon-induced rat lung tumors indicates similarities with human lung cancers. Genes Chromosomes Cancer. 2000;29(1):1–8
  18. Ishida T, Kaneko S, Yokoyama H, Inoue T, Sugio K, Sugimachi K. Adenosquamous carcinoma of the lung clinicopathologic and immunohistochemical features. Am J Clin Pathol. 1992;97(5):678–685
  19. Kikuchi T, Daigo Y, Katagiri T, Tsunoda T, Okada K, Kakiuchi S, et al. Expression profiles of non-small cell lung cancers on cDNA microarrays: identification of genes for prediction of lymph-node metastasis and sensitivity to anti-cancer drugs. Oncogene. 2003;22(14):2192–2205
  20. Yamagata N, Shyr Y, Yanagisawa K, Edgerton M, Dang TP, Gonzalez A, et al. A training-testing approach to the molecular classification of resected non-small cell lung cancer. Clin Cancer Res. 2003;9(13):4695–4704
  21. Kettunen E, Anttila S, Seppanen JK, Karjalainen A, Edgren H, Lindstrom I, et al. Differentially expressed genes in nonsmall cell lung cancer: expression profiling of cancer-related genes in squamous cell lung cancer. Cancer Genet Cytogenet. 2004;149(2):98–106
  22. Hofmann HS, Bartling B, Simm A, Murray R, Aziz N, Hansen G, et al. Identification and classification of differentially expressed genes in non-small cell lung cancer by expression profiling on a global human 59.620-element oligonucleotide array. Oncol Rep. 2006;16(3):587–595
  23. Boelens MC, van den Berg A, Vogelzang I, Wesseling J, Postma DS, Timens W, et al. Differential expression and distribution of epithelial adhesion molecules in non-small cell lung cancer and normal bronchus. J Clin Pathol. 2007;60(6):608–614
  24. Angulo B, Suarez-Gauthier A, Lopez-Rios F, Medina PP, Conde E, Tang M, et al. Expression signatures in lung cancer reveal a profile for EGFR-mutant tumours and identify selective PIK3CA overexpression by gene amplification. J Pathol. 2008;214(3):347–356
  25. Young GD, Winokur TS, Cerfolio RJ, Van Tine BA, Chow LT, Okoh V, et al. Differential expression and biodistribution of cytokeratin 18 and desmoplakins in non-small cell lung carcinoma subtypes. Lung Cancer. 2002;36(2):133–141
  26. Wikman H, Kettunen E, Seppanen JK, Karjalainen A, Hollmen J, Anttila S, et al. Identification of differentially expressed genes in pulmonary adenocarcinoma by using cDNA array. Oncogene. 2002;21(37):5804–5813
  27. Su YC, Hsu YC, Chai CY. Role of TTF-1, CK20, and CK7 immunohistochemistry for diagnosis of primary and secondary lung adenocarcinoma. Kaohsiung J Med Sci. 2006;22(1):14–19
  28. Miettinen M, Sarlomo-Rikala M. Expression of calretinin, thrombomodulin, keratin 5, and mesothelin in lung carcinomas of different types: an immunohistochemical analysis of 596 tumors in comparison with epithelioid mesotheliomas of the pleura. Am J Surg Pathol. 2003;27(2):150–158
  29. Camilo R, Capelozzi VL, Siqueira SA, Del Carlo Bernardi F. Expression of p63, keratin 5/6, keratin 7, and surfactant-A in non-small cell lung carcinomas. Hum Pathol. 2006;37(5):542–546
  30. Murata K, Ota S, Niki T, Goto A, Li CP, Ruriko UM, et al. p63—key molecule in the early phase of epithelial abnormality in idiopathic pulmonary fibrosis. Exp Mol Pathol. 2007;83(3):367–376
  31. Beckman G, Eklund A, Frohlander N, Stjernberg N. Haptoglobin groups and lung cancer. Hum Hered. 1986;36(4):258–260
  32. Dobashi Y, Shoji M, Jiang SX, Kobayashi M, Kawakubo Y, Kameya T. Active cyclin A-CDK2 complex, a possible critical factor for cell proliferation in human primary lung carcinomas. Am J Pathol. 1998;153(3):963–972
  33. Yuan A, Yu CJ, Chen WJ, Lin FY, Kuo SH, Luh KT, et al. Correlation of total VEGF mRNA and protein expression with histologic type, tumor angiogenesis, patient survival and timing of relapse in non-small-cell lung cancer. Int J Cancer. 2000;89(6):475–483
  34. Amatschek S, Koenig U, Auer H, Steinlein P, Pacher M, Gruenfelder A, et al. Tissue-wide expression profiling using cDNA subtraction and microarrays to identify tumor-specific genes. Cancer Res. 2004;64(3):844–856
  35. Jones JM, McGonigle NC, McAnespie M, Cran GW, Graham AN. Plasma fibrinogen and serum C-reactive protein are associated with non-small cell lung cancer. Lung Cancer. 2006;53(1):97–101
  36. Moldvay J, Jackel M, Paska C, Soltesz I, Schaff Z, Kiss A. Distinct claudin expression profile in histologic subtypes of lung cancer. Lung Cancer. 2007;57(2):159–167
  37. Kotoulas CS, Foroulis CN, Kostikas K, Konstantinou M, Kalkandi P, Dimadi M, et al. Involvement of lymphatic metastatic spread in non-small cell lung cancer accordingly to the primary cancer location. Lung Cancer. 2004;44(2):183–191
  38. Guo M, Akiyama Y, House MG, Hooker CM, Heath E, Gabrielson E, et al. Hypermethylation of the GATA genes in lung cancer. Clin Cancer Res. 2004;10(23):7917–7924
  39. Rieger E, Bijl JJ, van Oostveen JW, Soyer HP, Oudejans CB, Jiwa NM, et al. Expression of the homeobox gene HOXC4 in keratinocytes of normal skin and epithelial skin tumors is correlated with differentiation. J Invest Dermatol. 1994;103(3):341–346
  40. Ito T, Udaka N, Yazawa T, Okudela K, Hayashi H, Sudo T, et al. Basic helix-loop-helix transcription factors regulate the neuroendocrine differentiation of fetal mouse pulmonary epithelium. Development. 2000;127(18):3913–3921
  41. Carnaghi C, Rimassa L, Garassino I, Santoro A. Clinical significance of neuroendocrine phenotype in non-small-cell lung cancer. Ann Oncol. 2001;12(Suppl. 2):S119–S123
  42. Adjei AA. The role of mitogen-activated ERK-kinase inhibitors in lung cancer therapy. Clin Lung Cancer. 2005;7(3):221–223
  43. Greenberg AK, Basu S, Hu J, Yie TA, Tchou-Wong KM, Rom WN, et al. Selective p38 activation in human non-small cell lung cancer. Am J Respir Cell Mol Biol. 2002;26(5):558–564
  44. Coe BP, Lockwood WW, Girard L, Chari R, Macaulay C, Lam S, et al. Differential disruption of cell cycle pathways in small cell and non-small cell lung cancer. Br J Cancer. 2006;94(12):1927–1935
  45. Vicent S, Lopez-Picazo JM, Toledo G, Lozano MD, Torre W, Garcia-Corchon C, et al. ERK1/2 is activated in non-small-cell lung cancer and associated with advanced tumours. Br J Cancer. 2004;90(5):1047–1052
  46. Aviel-Ronen S, Blackhall FH, Shepherd FA, Tsao MS. K-ras mutations in non-small-cell lung carcinoma: a review. Clin Lung Cancer. 2006;8(1):30–38
  47. Kosaka T, Yatabe Y, Endoh H, Kuwano H, Takahashi T, Mitsudomi T. Mutations of the epidermal growth factor receptor gene in lung cancer: biological and clinical implications. Cancer Res. 2004;64(24):8919–8923
  48. Shigematsu H, Lin L, Takahashi T, Nomura M, Suzuki M, Wistuba II, et al. Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J Natl Cancer Inst. 2005;97(5):339–346
  49. Shibata T, Hanada S, Kokubu A, Matsuno Y, Asamura H, Ohta T, et al. Gene expression profiling of epidermal growth factor receptor/KRAS pathway activation in lung adenocarcinoma. Cancer Sci. 2007;98(7):985–991
  50. Zacharatos P, Kotsinas A, Tsantoulis P, Evangelou K, Kletsas D, Asimacopoulos PJ, et al. Relationship of the K-ras/c-mos expression patterns with angiogenesis in non-small cell lung carcinomas. Mol Med. 2001;7(9):590–597
  51. Plummer HK, Dhar M, Schuller HM. Expression of the alpha7 nicotinic acetylcholine receptor in human lung cells. Respir Res. 2005;6:29
  52. Bumming P, Nilsson O, Ahlman H, Welbencer A, Andersson MK, Sjolund K, et al. Gastrointestinal stromal tumors regularly express synaptic vesicle proteins: evidence of a neuroendocrine phenotype. Endocr Relat Cancer. 2007;14(3):853–863
  53. Willett CG, Smith DI, Shridhar V, Wang MH, Emanuel RL, Patidar K, et al. Differential screening of a human chromosome 3 library identifies hepatocyte growth factor-like/macrophage-stimulating protein and its receptor in injured lung Possible implications for neuroendocrine cell survival. J Clin Invest. 1997;99(12):2979–2991
  54. Linnoila RI, Mulshine JL, Steinberg SM, Funa K, Matthews MJ, Cotelingam JD, et al. Neuroendocrine differentiation in endocrine and nonendocrine lung carcinomas. Am J Clin Pathol. 1988;90(6):641–652
  55. Ionescu DN, Treaba D, Gilks CB, Leung S, Renouf D, Laskin J, et al. Nonsmall cell lung carcinoma with neuroendocrine differentiation—an entity of no clinical or prognostic significance. Am J Surg Pathol. 2007;31(1):26–32
  56. Sterlacci W, Fiegl M, Hilbe W, Auberger J, Mikuz G, Tzankov A. Clinical relevance of neuroendocrine differentiation in non-small cell lung cancer assessed by immunohistochemistry: a retrospective study on 405 surgically resected cases. Virchows Arch. 2009;455(2):125–132
  57. Pelosi G, Pasini F, Sonzogni A, Maffini F, Maisonneuve P, Iannucci A, et al. Prognostic implications of neuroendocrine differentiation and hormone production in patients with Stage I nonsmall cell lung carcinoma. Cancer. 2003;97(10):2487–2497
  58. Berridge MJ, Lipp P, Bootman MD. The versatility and universality of calcium signalling. Nat Rev Mol Cell Biol. 2000;1(1):11–21
  59. Roderick HL, Cook SJ. Ca2+ signalling checkpoints in cancer: remodelling Ca2+ for cancer cell proliferation and survival. Nat Rev Cancer. 2008;8(5):361–375
  60. Gudermann T, Roelle S. Calcium-dependent growth regulation of small cell lung cancer cells by neuropeptides. Endocr Relat Cancer. 2006;13(4):1069–1084
  61. Deberardinis RJ, Sayed N, Ditsworth D, Thompson CB. Brick by brick: metabolism and tumor cell growth. Curr Opin Genet Dev. 2008;18(1):54–61

PII: S0169-5002(09)00578-9

doi: 10.1016/j.lungcan.2009.11.001

Lung Cancer
Volume 68, Issue 1 , Pages 1-9 , April 2010

Article Tools

* Image Usage & Resolution